Small hepatitis B virus surface protein (S-HBsAg) variant Y100C has been associated with HBsAg-negative phenotype. To determine whether Y100C substitution yields impaired HBsAg or small amounts of HBsAg that may reduce HBsAg detection by commercial anti-HBsAg antibodies, two eukaryotic expression plasmids, one containing a wild-type S and the other an S gene from a Y100C variant, were construct...

T lymphocytes from 7 (21%) of 34 patients with chronic hepatitis showed positive cytotoxicity against HBsAg-coated Chang cells. This positivity was observed in HBsAg-negative patients having positive blast transformation responses to HBsAg, as well as in patients convalescing and recovered from acute B hepatitis. Levels of S-GPT in these patients were not different from those showing no cytotox...

BACKGROUND The kinetics of hepatitis B surface antigen (HBsAg) are predictive in HBV-infected patients treated with pegylated interferon. Knowledge about the value of HBsAg levels in patients coinfected with HBV and human immunodeficiency virus (HIV) is lacking. METHODS We quantified serum HBsAg in a Dutch multicenter cohort of 104 patients coinfected with HIV and HBV who were treated with te...

لا ةصلاخ : نأ مو لعملا ن م ويد يفلا ة جلاعم ي ف ر مزلا ة آرح ريد قت (video) ً ار يبآ اً ئبع ل ثمي جلا عملا ةد حو ي ف يزآرملا (CPU) . ة مءَلاملاو ثحبلا يروط نيسحتل ةعيرس تا يمزراوخ ريوطت مت كلذل . تا يمزراوخلا هذ ه يناكملا لقحلا يف لمعت . تا يمزراوخ يف ةرفوتملا تاعرسلا نم ديفتست ةديدج ةيمزراوخ حرتقن لاقملا اذه يفو ةعيرسلا هييروف (FFT) . ددحت ةحرتقملا ةيمزراوخلاو مادختساب يعجرملا راطلإاو ةرفشملا ةر...

BACKGROUND & AIMS Hepatitis B surface antigen (HBsAg) seroclearance and seroconversion are regarded as favorable outcomes of chronic hepatitis B (CHB). This study aimed to develop artificial neural networks (ANNs) that could accurately predict HBsAg seroclearance or seroconversion on the basis of available serum variables. METHODS Data from 203 untreated, HBeAg-negative CHB patients with spon...

In recent years the diagnostic industry has developed new automated immunoassays for the qualitative detection of hepatitis B virus (HBV) surface antigen (HBsAg) in serum and plasma samples that are performed on analyzers that permit a high-speed throughput, random access, and primary tube sampling. The aim of the present study was the evaluation of two new automated HBsAg screening assays, IMM...

The survey was carried out to determine the molecular detection of Hepatitis B virus markers among blood donors between age 18-65 years from National Blood Transfusion Service (NBTS) centre in Kaduna, Nigeria. samples were screened for (HBV) using Diagnostic kit HBV infection marker whole blood. serological determined polymerase chain reaction and confirmed. socio-demographic factors associated...

BACKGROUND & AIMS Quantitative HBsAg has been recognized to assist in the management of chronic hepatitis B virus (HBV) infection. However, its role in disease monitoring of HBeAg-negative patients remains unclear. We aimed to investigate the longitudinal HBsAg change in HBeAg-negative carriers with HBV genotype B or C infection. METHODS This is a retrospective cohort study conducted in a uni...

Mutations in hepatitis B virus surface antigen (HBsAg) involving amino acid substitution within the immunodominant "a" determinant may affect the performance of commercial HBsAg assays. The performances of four HBsAg assays that recently received Conformité Européene marking, Advia Centaur HBsAg (Bayer), Monolisa HBsAg Ultra (Bio-Rad), Liaison HBsAg (Dia Sorin), and Vidas HBsAg Ultra (bioMérieu...

BACKGROUND Hepatitis B surface antigen (HBsAg) loss/seroconversion is considered to be the ideal endpoint of antiviral therapy and the ultimate treatment goal in chronic hepatitis B (CHB). This study aimed to assess the patterns of HBsAg kinetics in CHB patients who achieved HBsAg loss during the treatment of pegylated interferon (PEG-IFN) α-2a. METHODS A total of 150 patients were enrolled, ...